CD47-targeted immunotherapy approaches aim to enhance anti-tumor immunity and improve clinical outcomes by disrupting the “don’t eat me” signal between CD47 (on cancer cells) and SIRPα (on myeloid cells). This evidence concerns the gene SIRPA and neoplasm.